ESTRO 2024 - Abstract Book

S1564

Clinical - Lower GI

ESTRO 2024

14. Xu N, Li W, Huang F, Yang J, Wen Z, Yin L, et al. Systemic inflammation-based predictors of pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. J Cancer Res Ther. 2022;18(2):438-44. 15. Jeon BH, Shin US, Moon SM, Choi JI, Kim MS, Kim KH, et al. Neutrophil to Lymphocyte Ratio: A Predictive Marker for Treatment Outcomes in Patients With Rectal Cancer Who Underwent Neoadjuvant Chemoradiation Followed by Surgery. Ann Coloproctol. 2019;35(2):100-6. 16. Chandramohan A, Mittal R, Dsouza R, Yezzaji H, Eapen A, Simon B, et al. Prognostic significance of MR identified EMVI, tumour deposits, mesorectal nodes and pelvic side wall disease in locally advanced rectal cancer. Colorectal Dis. 2022;24(4):428-38.

2982

Digital Poster

Short-course radiotherapy followed by chemotherapy for rectal cancer: Reflections on quality of life

Ghada Abdessatar, Mouna Ben Rejeb, Rim Moujahed, Ferdaws Friaa, Lilia Ghorbel, Lotfi Kochbati

Abderahmane Mami hospital, Radiation oncology, Ariana, Tunisia

Purpose/Objective:

Over the past decades, advances in the treatment of colorectal cancer have led to better survival rates and local disease control. Hence, quality of life (QOL) becomes an important parameter to assess. The aim of this study was to evaluate the immediate health-related QoL and toxicity outcomes of colorectal cancer survivors treated with curative intent.

Material/Methods:

The study surveyed 100 patients treated for rectal cancer according to the RAPIDO trial: short-couse radiotherapy (25 Gy/5 Gy in 5 fractions) and pre-operative chemotherapy followed by surgery. Radiotherapy was planned using 3D conformal technique.The European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30) and its complementary colorectal cancer specific questionnaire (EORTC QLQ-CR29) were applied to assess QOL after treatment completion. Acute toxicity was collected according to the Common Terminology Criteria for Adverse events, version 4.0 (CTCAE V4).

Results:

The median age was 61 years [33-70 years]. The male–female sex ratio was 1.7. Fifty percent of patients were treated for lower rectal cancer, 47% for middle rectal cancer and 3% had upper rectal cancer. All but 2 patients were diagnosed with stage III rectal cancer (AJCC 8th edition).Forty-six percent of patients underwent anterior resection, 40% underwent abdomino-perineal resection and 4 patients did not have surgery. Fifty-three patients had a temporary or permanent colostomy.After the completion of radiotherapy, 33% of patients reported acute toxicity. Seven patients showed a grade 1 diarrhea, 7% showed a grade 1 cystitis and 7% reported a mucositis.